Testosterone Cypionate

evidence score

anabolic

Scheduled Substance

241 studies

Test CypTCDepo-Testosterone+1 more

Testosterone Cypionate is a long-acting ester of testosterone, the primary endogenous male androgen. Approved for hypogonadism (TRT) and delayed puberty. The 8-day half-life allows weekly or twice-weekly injections, maintaining stable serum testosterone levels. The gold standard for TRT; extensively studied in clinical medicine. At supraphysiologic doses used in bodybuilding (200–600mg/week), it produces significant muscle hypertrophy, strength, and erythropoiesis but causes HPG axis suppression, erythrocytosis, and estrogen-related side effects via aromatization. Controlled substance (Schedule III).

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

Approved

Research Sync

Feb 19, 2026

Dosing

Typical

200 mg

100 mgRange600 mg

FrequencyIntramuscular injection weekly or E3.5D

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~8 days

Onset1–2 weeks for androgen effects; peak levels at 72 hours post-injection

DurationCycle length 8–16 weeks; suppression recovery 3–6 months without PCT

Routes

intramuscular

subcutaneous

Evidence Score

Level B — Moderate

241 studies indexed · 2 meta-analyses

Scoring Factors

Volume(40%)~48/100

Quality(30%)~45/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Testosterone Cypionate is currently categorized as a anabolic compound.

Evidence is moderate (72/100): promising signal from 241 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Binds androgen receptor as full agonist; activates muscle, bone, erythropoiesis, and CNS AR programs; aromatizes to estradiol via CYP19A1

Practical Context

Strongest current signals

Level B: Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY.
Level C: Testosterone Replacement Therapy in Men Aged 50 and Above: A Narrative Review of Evidence-Based Benefits, Safety Considerations, and Clinical Recommendations.
Level C: Management of Adverse Effects in Testosterone Replacement Therapy.

Elevated caution signals

1 severe/high side effect flag